Mechanistic systems biology models of brigatinib and alectinib obtained with TPMS technology were constructed with accuracy values of 94% to evaluate their mechanism of action and potential treatment efficacy in ALK+ NSCLC. Here, ALK is linked to non-small cell lung carcinoma.